Investors

Corporate Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Download Corporate Presentation

Aurinia Corporate Presentation June 2025

Forward-Looking Statements disclaimer from Aurinia. It cautions that the presentation contains forward-looking statements under U.S. and Canadian securities laws, which are based on current expectations and involve risks and uncertainties that could cause actual results to differ. Topics include revenue, product sales, clinical study outcomes, and regulatory filings. Additional information is available via SEDAR (www.sedarplus.ca), EDGAR (www.sec.gov/edgar), and www.auriniapharma.com.

Aurinia's strategy for autoimmune diseases includes two goals: (1) Continue LUPKYNIS commercial growth and (2) Advance AUR200 development. The message "Changing the Trajectory of Autoimmune Diseases" is displayed on the left.

Lupkynis is the first FDA-approved oral therapy for treating lupus nephritis. A bar chart shows increasing net product sales from 2021 to 2025:

$45.5M in 2021
$103.5M in 2022
$158.5M in 2023
$216.2M in 2024
2025 guidance range: $240M to $250M
An upward orange arrow indicates steady growth. Source: Aurinia, with 2025 guidance as of February 27, 2025.

About Lupus Nephritis

Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease. Over 200,000 people in the U.S. have SLE, and 20–60% develop LN. A graphic highlights that LN affects up to 120,000 people in the U.S. It explains that LN occurs when the immune system attacks the kidneys, disproportionately affects women and people of color, and causes protein in the urine, which is used to monitor disease and treatment. Inflammation can lead to impaired kidney function or failure.

Bar chart titled “LN Class by Proteinuria in Patients with SLE” shows that proteinuria is a significant risk factor for kidney damage. Among patients with proteinuria less than 0.5 g/day, 89.1% had severe LN class (III, IV, or V), while among those with ≥0.5 g/day, 99.4% had severe LN class. Only 10.9% and 0% had class II, respectively. Caption: Nearly 90% of patients with proteinuria <0.5 g/day have class III, IV, or V on biopsy.

Line graph shows that even a single flare of lupus nephritis (LN) can reduce kidney lifespan. The red line shows gradual decline in kidney function (GFR) with aging. The blue line shows faster decline after a single LN episode, and the purple line shows the steepest decline with ongoing LN. By age 100, the red line reaches CKD stage 3, while the blue and purple lines progress to stage 5. Caption: Nephron and podocyte loss lead to kidney damage as measured by GFR and proteinuria.

Line graph titled “Kidney Survival Based on Proteinuria Response Status” shows that greater proteinuria reduction is linked to long-term renal protection. At 10 years, kidney survival was 94% for patients with a complete response, 45% for partial response, and 19% for no response. The graph shows that better proteinuria response leads to higher kidney survival over time.

Lupkynis is a novel, structurally modified calcineurin inhibitor (CNI) that targets lupus nephritis with a dual mechanism of action: (1) Immunosuppression—acts by inhibiting T-cell activation and cytokine production, and (2) Podocyte stability—promotes podocyte stability to reduce proteinuria. Presented under a banner labeled “Targeted Dual Mechanism of Action.”

Bar graphs from the AURORA 1 study show that significantly more patients on Lupkynis achieved a complete renal response (CRR) compared to placebo. At week 52, 40.8% of patients on Lupkynis + MMF + corticosteroids achieved CRR vs. 22.5% on placebo + MMF + corticosteroids, making Lupkynis patients 81% more likely to achieve CRR. At week 24, 32.4% on Lupkynis achieved CRR vs. 19.7% on placebo, a 64% improvement.

Slide titled “LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1.” Two bar graphs show that patients receiving LUPKYNIS plus MMF and corticosteroids experienced faster reductions in proteinuria than those on placebo.
Left graph: Median time to UPCR ≤0.5 mg/mg was 169 days for LUPKYNIS vs. 372 days for placebo — a 203-day improvement.
Right graph: Median time to 50% UPCR reduction was 29 days for LUPKYNIS vs. 63 days for placebo — a 34-day improvement.
Conclusion: LUPKYNIS cut proteinuria in half the time compared to standard treatment alone.

Table shows adverse reactions that occurred in ≥3% of patients treated with Lupkynis 23.7 mg twice daily and ≥2% more often than placebo in AURORA 1 and AURA-LV trials. Top adverse events for Lupkynis included decreased glomerular filtration rate (26%), hypertension (19%), diarrhea (19%), and headache (15%). Placebo group showed lower rates for most events. A note states that AURORA 2 confirmed Lupkynis had no unexpected safety signals over 3 years.

New American College of Rheumatology (ACR) Guideline Support Earlier Usage of LUPKYNIS.

The 2024 ACR Guideline for treating lupus nephritis recommends triple immunosuppressive therapy, including a calcineurin inhibitor (CNI) as first-line. Goals include reducing proteinuria to ≤0.5 mg/mg within 6–12 months and reducing corticosteroid use to ≤5 mg/day by 6 months. Lupkynis is the only FDA-approved CNI for LN. It achieved median proteinuria reduction to target in under 6 months, and 81% of patients were on ≤2.5 mg/day of steroids by week 16.

AUR200 – A dual BAFF/APRIL inhibitor for the potential treatment of autoimmune diseases.

Slide explains that AUR200 is a dual BAFF/APRIL inhibitor. It contains a BCMA-engineered extracellular domain with superior affinity for BAFF and APRIL, unlike others that use TACI. BCMA has stronger natural affinity for APRIL. AUR200 also includes an IgG4 Fc domain with minimal immune activation, making it less inflammatory than IgG1-based therapies. An illustration on the right shows AUR200 binding to BAFF and APRIL with labeled components.

Slide titled “Role of BAFF and APRIL” explains that these cytokines regulate B cell survival and differentiation at various development stages. Targeting both BAFF and APRIL with AUR200 may prevent autoreactive B cell activation and reduce antibody levels. A diagram below shows B cell maturation from stem cells to plasma cells and memory B cells, highlighting stages dependent on BAFF and APRIL.

Slide titled “AUR200 Is a High Affinity Dual BAFF/APRIL Inhibitor.” A table compares the binding affinity (Kd, in pM) of AUR200, Atacicept, and Telitacicept to BAFF and APRIL.

AUR200 shows the strongest binding: 117 pM to BAFF and 25 pM to APRIL.
Atacicept: 919 pM to BAFF (7.9x weaker), 67 pM to APRIL (2.7x weaker).
Telitacicept: 616 pM to BAFF (5.3x weaker), 82 pM to APRIL (3.3x weaker).
Conclusion: AUR200 has the highest affinity among the compared inhibitors.

Graphs and data table show that AUR200 potently inhibits B cell proliferation driven by BAFF and APRIL. In dose-response curves, AUR200 shows stronger suppression compared to Atacicept and Telitacicept. AUR200’s IC₅₀ is 0.02 nM for BAFF and 0.37 nM for APRIL. Compared to AUR200, Atacicept is 19x less potent for BAFF and 5.8x for APRIL; Telitacicept is 52.5x and 11.2x less potent. Caption: AUR200 potently inhibits both BAFF- and APRIL-mediated B cell proliferation versus competitor inhibitors.

Line graphs show that AUR200 depletes B cell antibodies IgA and IgM in non-human primates. After 4 weekly doses, IgA was reduced by up to 76% and IgM by up to 67%, depending on dosage. Higher doses (20 and 80 mg/kg) resulted in the greatest reductions. Vehicle-treated animals showed no significant change. AUR200 was well-tolerated with no adverse findings across all tested doses.

Diagram of the AUR200 Single Ascending Dose (SAD) study design. The study includes up to 5 weeks of screening, 1 week of in-clinic observation, and 13 weeks of outpatient visits. Five cohorts of 8 healthy volunteers each (6 receiving AUR200, 2 receiving placebo) are shown progressing sequentially through Dose 1 to Dose 5. The study began in September 2024 and is expected to report initial results in Q2 2025.

Financial Overview

Table titled “2024 Financial Highlights” compares Aurinia’s 2023 and 2024 performance.

Total Revenue increased from $175.5M to $235.1M (up 34%)
Net Product Sales rose from $158.5M to $216.2M (up 36%)
License, Collaboration, and Royalty Revenue grew from $17.0M to $18.9M (up 11%)
Net Income improved from a loss of $78.0M to a gain of $5.8M
Operating cash flow improved from $(33.5)M to $44.4M
A note states that as of December 31, 2024, Aurinia had $358.5M in cash and no debt.

Table titled “2025 Financial Guidance” compares 2024 actuals with projected 2025 ranges.

Total revenue in 2024 was $235.1 million. 2025 guidance is $250.0M (up 6%) to $260.0M (up 11%).
Net product sales in 2024 were $216.2 million. 2025 guidance is $240.0M (up 11%) to $250.0M (up 16%).
Note states guidance is as of February 27, 2025.

Aruinia Pharmaceuticals, Inc. 2025. All rights reserved. Trademarks and logos are the property of Aurinia Pharmaceuticals, Inc.

Email Alerts

Thank you! Your message has been sent!

Oops! There was an error with your submission.

Stock Information

NASDAQ Global Market: AUPH

$8.64

+0.01

/

+0.12%

4,365,611

Volume

Last update:

Jun 27, 2025 4:00 PM ET

Pricing delayed by 15 minutes

Upcoming Events

Jun 30

-

Jun 30, 2025 8:30 AM

EDT

2025

Conference Call to Discuss AUR200 Phase 1 Study Results

Press Release Webcast Presentation

Past Events

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Sep 20

-

Sep 20, 2021 2:55 PM

EDT

2021

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Press Release Webcast Presentation Financials and MDA - IFRS Financials - US GAAP Financials and MDA

Sep 13

-

Sep 15, 2021

Sep 13, 2021 12:00 AM

2021

H.C. Wainwright 23rd Annual Global Investment Conference

Press Release Webcast Presentation Financials and MDA - IFRS Financials - US GAAP Financials and MDA

Aug 10

-

Aug 10, 2021 2:50 PM

EDT

2021

BTIG Virtual Biotech Conference

Press Release Webcast Presentation Financials and MDA - IFRS Financials - US GAAP Financials and MDA

Aug 5

-

Aug 5, 2021 4:30 PM

EDT

2021

Second Quarter 2021 Financial Results Conference Call

Press Release 10-Q Webcast Presentation Financials and MDA - IFRS Financials - US GAAP Financials and MDA

Jun 7

-

Jun 7, 2021 8:00 AM

EDT

2021

2021 Annual General Meeting

Press Release Webcast Presentation Financials and MDA - IFRS Financials - US GAAP Financials and MDA

No Results Found

Please try different keywords or filters.

SEC Filings

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Date

Filing Type

Description

Download

Date

March 4, 2025

2025

Filing Type

Description

Statement of Changes in Beneficial Ownership

Section 16 Filings

Date

March 4, 2025

2025

Filing Type

Description

Statement of Changes in Beneficial Ownership

Section 16 Filings

Date

March 4, 2025

2025

Filing Type

Description

Statement of Changes in Beneficial Ownership

Section 16 Filings

Date

March 4, 2025

2025

Filing Type

Description

General Statement of Acquisition of Beneficial Ownership

Other

Date

March 4, 2025

2025

Filing Type

Description

Statement of Changes in Beneficial Ownership

Section 16 Filings

No Results Found

Please try different keywords or filters.

IR Contact

General inquiries can be sent to ir@auriniapharma.com